PeptideDB

8α,9α-Epoxycoleon-U-quinone 93800-59-0

8α,9α-Epoxycoleon-U-quinone 93800-59-0

CAS No.: 93800-59-0

8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) modulator with selectivity for cancer/tumor cells
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) modulator with selectivity for cancer/tumor cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone can effectively inhibit P-gp activity in NCI-H460/R cells, and when combined with Doxorubicin (DOX), reverse the resistance of cancer/tumor cells to DOX and enhance Anti-cancer effects of DOX.

Physicochemical Properties


CAS # 93800-59-0
Appearance Typically exists as solid at room temperature
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro 8α,9α-Epoxycoleon-U-quinone (2, 5, 10, 20, 50 μM; 72 h) has a selectivity index of 2.0 [1], meaning it is specific for cancer cell lines. P-glycoprotein (P-gp) activity in NCI-H460/R cells can be inhibited by 8α,9α-Epoxycoleon-U-quinone (10 μM; 72 h) [1]. The anti-cancer activity of DOX can be enhanced and cancer cell resistance to DOX reversed by 8α,9α-Epoxycoleon-U-quinone (1,2,5 μM; 72 h) [1].
Cell Assay Cell viability assay [1]
Cell Types: NCI-H460/R Cell
Tested Concentrations: 10 μM
Incubation Duration: 72 h
Experimental Results: Rho123 accumulation in NCI-H460/R cells was diminished and had no effect on ABCB1 expression.

Cell viability assay[1]
Cell Types: NCI-H460/R Cell
Tested Concentrations: 1, 2, 5 μM (Combined with Doxorubicin (DOX))
Incubation Duration: 72 hrs (hours) (Pretreatment)
Experimental Results: Promotion of NCI-H4l60/ The relative reversal indices of sensitized R cells to DOX were 1.976 and 4.696 (concentrations of 1 and 2 μM), respectively.
References

[1]. C20-nor-Abietane and Three Abietane Diterpenoids from Plectranthus mutabilis Leaves as P-Glycoprotein Modulators. ACS Med Chem Lett. 2022 Mar 11;13(4):674-680.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)